Thanks for the historical perspective on the U.K. situation.
"The missing number is 1,700,000 when you follow the cash
and on a tight budget"
Sorry Wolf, this statement is a little too cryptic for me. Are you saying that $1,700,000 Cdn would be a target income from Pennsaid sales in the U.K.?
Further to my comments on JnJ. Some have questioned why JnJ was not first selected to market Pennsaid in the U.K. Perhaps it's because JnJ feels it crucial that Pennsaid be marketed properly, (aren't there 58 topicals in Great Britain alone). Surely, the recent experience there has conclusively shown how important the marketing effort must be.
At the time Dimethaid was ready to go in Britain, JnJ probably felt the effort was doomed to failure given the laws in that country.
Providing we are prepared to accept a few 'ifs' the situation could now be changing. If regulatory approval is coming to a continent near us, and if JnJ will market Pennsaid in the US, and if JnJ is guiding development of a sophisticated marketing plan, then they may believe that a strong campaign in North America will cross over to English speaking UK.
Therefore, it may very well be that JnJ is ready to go in the British market. If it is, then we can erase all those 'ifs'. |
